Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jul 26, 2021 10:54am
WHOSE SIDE IS THE CEO ON? US (Commons) or THEM (Cobras)?
BB
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jul 19, 2021 7:26pm
FLOWERS FOR ALGERNON'S CEO
BB
Debt-Free and Thriving: Mining Company Reports 35% Revenue Growth in Q3 2024
posted Nov 12, 2024 9:00am by
Mandalay Resources Corp.
-
|
"Revenue growth and free cash flow generation reflect our cost controls and prudent capital management while benefitting from high metal prices. As of the end of Q3 our cash balance was a healthy $54.7 million – more than doubling since December 2023 – and we have fully repaid the $20 million outstanding balance on our revolving credit facility, strengthening our liquidity and financial flexibility ...read more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jul 17, 2021 9:38am
What's In A Company Name?
Let Christopher Moreau tell it, he and the Board Of Directors had to convince (arm twisting) the former CSO, Dr. Mark Williams, the name Algernon was a good idea. So what motivated the Board Of
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Comment by
BlaineBorg
on Jul 15, 2021 11:40pm
RE:RE:RE:What is the reason
Christopher Moreau, the CEO is in bed with Kulwant Malhi. The #1 common shareholder and institutional investors of Algernon stock. He has gone to work for Kulwant Malhi at First Responder Technologies
...more
(23)
•••
Flyer47
X
View Profile
View Bullboard History
Comment by
Flyer47
on Jul 15, 2021 7:55pm
RE:RE:What is the reason
Agreed, he needs to relese the meeting minutes to show a minimum of good faith. Otherwise we can not return to tusting him.
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jul 15, 2021 10:33am
Thank You Christopher Moreau, CEO @ AP. The $tock Is Free!!!
F R E E ~ F A L L I N G
BB
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Comment by
BlaineBorg
on Jul 14, 2021 8:08am
RE:What is the reason
Agreed. Release The FDA's "OFFICIAL MEETING MINUTES" to ALL shareholders ASAP. There is zero reason to blindly trust what the CEO claims in the news release. Demand respect and demand
...more
(2)
•••
amendis
X
View Profile
View Bullboard History
Post by
amendis
on Jul 13, 2021 10:48pm
What is the reason
What is the reason Ifonprodi drop out 3 phase. what FDA said its not worth to go? 30 years go ONE coo said FDA not treat Canadian companies not treat fairly. NO death find in and doctors said drug is
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jul 12, 2021 1:21pm
BOTTOMLINE: IF IPF/CC STUDY IS DEEMED A SUCCESS THEN WHAT?
What is Christopher J. Moreau's plan moving forward? Is it another larger Phase 2 study or Phase 3 study? Will he pursue a partnership/licensing deal or go it alone? We simply don't know the
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jul 11, 2021 4:18pm
MY TOPLINE QUESTIONS FOR CHRISTOPHER J. MOREAU, CEO @ AP
My best guess as to the IPF/CC clinical trial is it will be a stepping stone to another Phase 2 study in the same vein as Bellus Health taking a second bite at the apple. I'm finding it hard to
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jul 10, 2021 3:33pm
Cyndi Edwards @ Streetwise Live! Asks The #1 Question
Cyndi Edwards: Dr. Nutt, on a scale from 1 to 10, how hopeful are you about the possibilities with DMT and helping stroke victims? Dr Nutt: I'm saying I'm currently at a 3, but I'm hoping
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Comment by
BlaineBorg
on Jul 08, 2021 8:47pm
RE:RE:RE:Enrollment Rate Is 1.27 Patients Per Month For IPF & CC.
My best guess is this company would still have more stability if he'd just kept peddling the FAIMS device versus tossing it away. Afterall he did make himself a living off two failed medical
...more
(23)
•••
Flyer47
X
View Profile
View Bullboard History
Comment by
Flyer47
on Jul 08, 2021 4:45pm
RE:RE:Enrollment Rate Is 1.27 Patients Per Month For IPF & CC.
Just more bait and switch from this clown. He just trys to change the subject to get to the next PR. Very sad way of managing of a company that should be doing better. If just one prediction came to
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Post by
BlaineBorg
on Jul 08, 2021 9:30am
Total Population in Australia and New Zealand: 30 Million
Total Population in North America: 370 Million. small minds do small things. L8 TERM ADVICE: THINK BIG OR GO HOME CEO. https://www.worldometers.info/world-population/australia-and-new-zealand
...more
(17)
•••
BlaineBorg
X
View Profile
View Bullboard History
Comment by
BlaineBorg
on Jul 08, 2021 1:25am
RE:Enrollment Rate Is 1.27 Patients Per Month For IPF & CC.
Correction: 5 Months until full enrollment. 6 Months until final treatment. Fully compiled data readout... Who knows, but I suspect 9 months from now. You do the math. Christopher Moreau is pleased. I
...more
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Meet the Top 5 Best Online Brokerages in Canada
Gold, growth and sustainability in focus for this resource company
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
Star Diamond Corporation Announces Third Quarter 2024 Results
Explained: The Psychology of Options Trading with Practical Tips
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023